Gastroparesis: Quality of Life and Symptom Burdens for Patients

Studies show that gastroparesis, a chronic gastrointestinal (GI) disorder, is estimated to affect up to five million people in the United States. The symptoms of this condition can be debilitating and sometimes life-threatening.

Throughout the month of August, the International Foundation for Gastrointestinal Disorders (IFFGD) will raise awareness about the symptom burdens and quality of life for those living with gastroparesis – the theme for Gastroparesis Awareness Month 2020. “Patients living with this digestive disorder may suffer from a variety of symptoms which pose a tremendous impact on their daily lives,” says IFFGD president, Ceciel T. Rooker.

Gastroparesis Awareness Month, established by IFFGD in 2016, takes place every year during the month of August. During this time and throughout the year IFFGD utilizes their platform to support the gastroparesis community by raising awareness to promote education and encourage research.

Gastroparesis, also called delayed gastric emptying, is a chronic digestive condition characterized by symptoms that can vary from life-limiting to life-threatening and often persist or reoccur over time. Some refer to it as having a paralyzed stomach (Gastro = Stomach and Paresis = paralysis). Symptoms usually occur during or after a meal and can appear suddenly or gradually.

Symptoms typically include: 

  • Nausea and/or vomiting
  • Stomach pain and discomfort
  • Dry heaves
  • Stomach fullness after a normal-sized meal
  • Early fullness and the inability to finish a meal

Additionally, “the symptoms of gastroparesis – nausea, vomiting, stomach fullness, can affect patients differently, with different severities. In some patients, the nausea is bad, whereas in others, the abdominal pain can be particularly severe,” says Temple University’s Gastroenterology Vice Chair of Research, Henry P. Parkman, MD.

In recognition of Gastroparesis Awareness Month, IFFGD will launch a campaign that acknowledges the symptom burdens and quality of life for patients — using the hashtags #MyGPlife and #GastroparesisAwarenessMonth. “Many patients with gastroparesis, as well as their caregivers, are greatly affected by the burden afflicted in gastroparesis,” said Dr. Parkman. During Gastroparesis Awareness Month, we invite you to share your story about what it is like living with gastroparesis using #MyGPlife.

Find the Gastroparesis Awareness Month Media Toolkit and campaign images by visiting here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”